{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:57:04Z","timestamp":1792000624965,"version":"4.4.0"},"reference-count":21,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,29]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM), including obstructive HCM (oHCM), is the most common inherited cardiomyopathy causing lifestyle-limiting symptoms. Data are lacking about patients\u2019 perspectives on the daily impact of their symptoms. This qualitative interview study was conducted to better understand patients\u2019 experiences with oHCM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In October 2019, telephone interviews were conducted with 20 US adults with oHCM identified by the Hypertrophic Cardiomyopathy Association. Using a semi-structured interview guide, key symptoms, impacts of oHCM and oHCM treatment goals were discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median age was 54 years (range 29\u201378), 55% were women, 85% were white and 15% were Hispanic or Latino. Median time since diagnosis was 3 years. Symptoms included shortness of breath, dizziness\/light-headedness, heart palpitations\/fluttering (all 95%), fatigue (90%) and chest pain\/pressure (80%). All participants reported limitations in physical functioning\/activities; most reported additional impacts (emotional stress (80%), fear of dying (55%)). Shortness of breath and fatigue were among their most bothersome symptoms; an effective oHCM treatment would need to improve \u22651 of these symptoms (allowing increased physical\/social activity).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with oHCM experience a high symptom burden and psychosocial impacts, affecting health status. Improved shortness of breath, fatigue and physical functioning are highly valued by patients and represent important treatment goals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-081323","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T21:25:15Z","timestamp":1726608315000},"page":"e081323","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-6097","authenticated-orcid":false,"given":"Supriya","family":"Shore","sequence":"first","affiliation":[{"name":"Institute for Healthcare Policy & Innovation, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ervin","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kosa","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Fehnel","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Salberg","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Association, Denville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Butzner","sequence":"additional","affiliation":[{"name":"Cytokinetics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Heitner","sequence":"additional","affiliation":[{"name":"Cytokinetics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Cytokinetics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2025101815194305000_14.9.e081323.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.019"},{"key":"2025101815194305000_14.9.e081323.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1710575"},{"key":"2025101815194305000_14.9.e081323.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"2025101815194305000_14.9.e081323.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.011"},{"key":"2025101815194305000_14.9.e081323.5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2025101815194305000_14.9.e081323.6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","article-title":"Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"79","author":"Dybro","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025101815194305000_14.9.e081323.7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025101815194305000_14.9.e081323.8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter","volume":"11","author":"Masri","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025101815194305000_14.9.e081323.9","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3016"},{"key":"2025101815194305000_14.9.e081323.10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s41669-022-00335-5","article-title":"Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument","volume":"6","author":"Reaney","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"2025101815194305000_14.9.e081323.11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025101815194305000_14.9.e081323.12","unstructured":"Patton M . Qualitative evaluation and research methods. London, England: Sage Publications, 1990."},{"key":"2025101815194305000_14.9.e081323.13","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"2025101815194305000_14.9.e081323.14","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-020-00269-8","article-title":"Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life","volume":"4","author":"Zaiser","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2025101815194305000_14.9.e081323.15","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025101815194305000_14.9.e081323.16","unstructured":"U.S. Food and Drug Administration . Treatment for heart failure: endpoints for drug development guidance for industry 2019, Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry"},{"key":"2025101815194305000_14.9.e081323.17","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.cardfail.2023.05.020","article-title":"\u201cI Just Wanted Nothing More Than to Get in a Real Shower\u201d: Patient Experience of the Inpatient Wait for a Heart Transplant","volume":"29","author":"Salerno","year":"2023","journal-title":"J Card Fail"},{"key":"2025101815194305000_14.9.e081323.18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cardfail.2022.04.014","article-title":"Digging Deeper: Understanding Trajectories and Experiences of Shared Decision-Making for Primary Prevention ICD Implantation","volume":"28","author":"Rao","year":"2022","journal-title":"J Card Fail"},{"key":"2025101815194305000_14.9.e081323.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.07.011"},{"key":"2025101815194305000_14.9.e081323.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2010.06.003"},{"key":"2025101815194305000_14.9.e081323.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.694158"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-081323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:19:49Z","timestamp":1760825989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-081323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,17]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjopen-2023-081323"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-081323","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}